For example, 2024’s biopharma IPO market began promisingly with $3.6 billion in total funding in Q1 – the highest in several ...
Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...
Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2025 Preview report featuring updated forecasts for the biopharma market for 2025.
Immix Biopharma (IMMX) announced completion of the six-patient Phase 1b safety run-in segment in the U.S. NEXICART-2 study of NXC-201, an ...
About NXC-201 NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy. Initial data from Phase 1b/2 ex-U.S. study NEXICART-1 has demonstrated high complete ...
The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...
Year to date, shares of Sutro Biopharma have gained 16.8% compared with the industry’s 1.4% growth. Image Source: Zacks Investment Research The planned REFRαME-L1 study will evaluate the safety ...
Another publicly traded company has joined the growing ranks of firms incorporating cryptocurrencies into their treasury ...
2024--Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") reports interim results near the completion of Part 1 of its Deltacel-01 Phase 1 clinical trial. This trial is evaluating ...